Key result
Combined SS31 and entresto therapy was superior to either drug alone in preserving left-ventricular ejection-fraction and protecting heart structural integrity against doxorubicin-induced damage (p<0.0001).
Why the study?
To test whether early administration of SS31 and entresto combined is superior to either agent alone in preserving heart function in doxorubicin-induced dilated cardiomyopathy.
Does the combination of SS31 and sacubitril/valsartan improve left-ventricular ejection fraction in a rat model of doxorubicin-induced dilated cardiomyopathy?
Does the combination of SS31 and sacubitril/valsartan improve left-ventricular ejection fraction in a rat model of doxorubicin-induced dilated cardiomyopathy?
p-value: p=<0.0001
Combined SS31 and sacubitril/valsartan therapy provides superior protection of heart structural and functional integrity against doxorubicin-induced dilated cardiomyopathy compared to either treatment alone in a rat model.
Does not support clinical use against doxorubicin cardiotoxicity; leaves open translation of combined SS31-entresto benefits to patients.
This study tested the hypothesis that early administration of SS31 and entresto (En) was superior to either one alone on preserving the heart function in setting of dilated cardiomyopathy (DCM) induced by doxorubicin (Dox) [accumulated dosage of 12.5 mg/kg/administered by intraperitoneal (IP) at 4 separated time points within 20 days] in rat. Adult-male SD rats (n = 40) were equally categorized into groups 1 (sham-control), 2 (DCM), 3 (DCM + SS31/0.7 mg/kg/day/IP, since day-14 after DCM induction to day-60), 4 [DCM + En (30 mg/kg/day/orally since day-14 after DCM induction to day-60)] and 5 (DCM + combined SS31-En), and animals were euthanized by day 60. By day 60, left-ventricular ejection-fraction (LVEF) was highest in group 1, lowest in group 2 and significantly higher in group 5 than in groups 3 and 4 (all p < 0.0001), but it showed no difference between groups 3/4. The microscopic study showed that the fibrosis area/cardiomyocyte size and DNA-damaged (γ-H2AX+)/inflammatory (CD14+//CD68+) markers, and flow analysis of inflammatory (Ly6G+/MPO+/CD11b/c+) and early/late apoptosis (AN-V+/PI-//AN-V+/PI+) cells exhibited an opposite pattern of LVEF among the five groups (all p < 0.0001). The protein expressions of inflammatory upstream (TLR2/TLR4/MyD88/Mal/ TRAF6/IKK-α/IKK-ß) and downstream (p-NF-κb/TNF-α/IL-1ß/MMP-9), oxidative-stress/mitochondrial-damaged (NOX-1/NOX-2/cytosolic cytochrome-C/cyclophilin-D/DRP1) and autophagic/apoptotic (ratio of LC3B-II/LC3B-I and mitochondrial-Bax/caspase3/9) signaling pathways also exhibited an opposite pattern of LVEF among the five groups (all p < 0.0001). Combined SS31-En therapy was superior to either one alone on protecting the heart structural and functional integrities against Dox-induced DCM damage.
No takes yet. Share an insight, caveat, or question.
Yeh et al. (2021) studied Doxorubicin-induced dilated cardiomyopathy (n=40). Combination of SS31 and entresto vs. Sham-control, DCM alone, or either drug alone was evaluated on Left-ventricular ejection-fraction (LVEF) (p=<0.0001). Combined SS31 and entresto therapy was superior to either drug alone in preserving left-ventricular ejection-fraction and protecting heart structural integrity against doxorubicin-induced damage (p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: